US Capital Global Securities Closes $10MM Financing for Cardax, Inc.
Global private financial group supports the growth of development-stage biopharmaceutical company combatting cardiovascular disease, arthritis, and aging.
SAN FRANCISCO, FEBRUARY 2021 – US Capital Global Securities LLC, an affiliate of US Capital Global, is pleased to announce that it has provided customized advisory services for Cardax, Inc. (“Cardax”), as well as an offer of $10 million in equity financing. Headquartered in Honolulu, Hawaii, Cardax (OTCQB: CDXI) is a biopharmaceutical company focused primarily on developing pharmaceuticals to safely address chronic inflammatory disease. Cardax also markets ZanthoSyn®, a physician-recommended dietary supplement for health and longevity.
Headquartered in San Francisco, US Capital Global is a full-service private financial group with an established track record in corporate finance, asset management, and capital formation services. All private placements, securities, and other related services are offered by the group’s FINRA-member broker dealer affiliate, US Capital Global Securities LLC.
“Cardax’s mission is to safely combat chronic inflammation, one of the major drivers of chronic disease, including cardiovascular disease, metabolic disease, liver disease, arthritis, and aging,” said Charles Towle, CEO at US Capital Global Securities. “At an inflection point in its growth, Cardax sought $10 million in financing to advance its lead pharmaceutical candidate, CDX-101, from pre-clinical to clinical development. US Capital Global Securities provided customized advisory services for Cardax and secured $10 million in financing for the company.”
About Cardax, Inc.
Cardax is a biopharmaceutical company focused primarily on developing pharmaceuticals for diseases driven by inflammation. The company also has a commercial business unit that markets ZanthoSyn®, an astaxanthin dietary supplement for inflammatory health. CDX-101, the company’s astaxanthin pharmaceutical candidate, is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. CDX-301, the company’s zeaxanthin pharmaceutical candidate, is being developed for macular degeneration. The safety and efficacy of the company’s pharmaceutical candidates have not been directly evaluated in clinical trials or confirmed by the FDA. www.cardaxpharma.com
About US Capital Global
US Capital Global Securities LLC (“USCGS”) is the FINRA-registered broker-dealer division of US Capital Global that acts as placement agent for growth-stage companies, projects, and investment funds. Since 1998, the US Capital Global team has been committed to providing small and lower middle market businesses and investors with sophisticated debt, equity, and investment opportunities usually available only to larger middle market companies and institutional investors, using the latest FinTech and RegTech innovation. US Capital Global entities manage direct investment funds and provide wealth management and capital raise services. View USCGS’ Form CRS at www.uscgs.com/crs.html.
To learn more about US Capital Global Securities or this investment opportunity, email Frank Villarreal at fvillarreal@uscapglobal.com or call +1 415-350-4092.
